MannKind Corporation develops inhaled therapies and devices targeting diabetes, pulmonary hypertension, heart failure, and chronic kidney disease. Historically, its growth has been underpinned by Afrezza inhaled insulin sales, the acquisition of V-Go, royalties from United Therapeutics’ Tyvaso DPI, and more recently the 2025 scPharma acquisition. With FDA label updates and pediatric Afrezza trials underway, MannKind aims to expand Afrezza adoption. However, commercial success remains concentrated in a limited product portfolio, exposing MannKind to regulatory uncertainties and manufacturing dependencies. Financially, the company shows positive operating income in 2025 but negative equity persists post-heavy investments and acquisitions.